NASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis $2.20 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.20▼$2.3050-Day Range$1.90▼$2.8352-Week Range$1.62▼$4.05Volume1,388 shsAverage Volume6,183 shsMarket Capitalization$57.05 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Anebulo Pharmaceuticals alerts: Email Address Anebulo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside203.0% Upside$6.67 Price TargetShort InterestHealthy0.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.05Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.47) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.13 out of 5 starsMedical Sector617th out of 936 stocksPharmaceutical Preparations Industry285th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAnebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnebulo Pharmaceuticals has received no research coverage in the past 90 days.Read more about Anebulo Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.16% of the float of Anebulo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAnebulo Pharmaceuticals has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anebulo Pharmaceuticals has recently increased by 15.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnebulo Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnebulo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANEB. Previous Next 2.8 News and Social Media Coverage News SentimentAnebulo Pharmaceuticals has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.90% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.40% of the stock of Anebulo Pharmaceuticals is held by institutions.Read more about Anebulo Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anebulo Pharmaceuticals are expected to decrease in the coming year, from ($0.47) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anebulo Pharmaceuticals is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anebulo Pharmaceuticals is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnebulo Pharmaceuticals has a P/B Ratio of 5.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anebulo Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Read More ANEB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANEB Stock News HeadlinesJuly 22, 2024 | businesswire.comAnebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic EffectsJuly 16, 2024 | americanbankingnews.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Growth in Short InterestJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | investorplace.comANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024May 15, 2024 | finance.yahoo.comAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesMay 15, 2024 | businesswire.comGalehead Development to Collaborate With Rivian Automotive on Renewable Energy Project DevelopmentApril 17, 2024 | morningstar.comAnebulo Pharmaceuticals Inc 214April 2, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Abivax SA Sponsored ADR (ABVX)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 26, 2024 | msn.comMilestone rallies 23% on FDA update for tachycardia drugFebruary 16, 2024 | markets.businessinsider.comAnebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA TrackFebruary 15, 2024 | msn.comNew Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What’s the Latest?February 14, 2024 | msn.comSubstance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication DrugFebruary 13, 2024 | finance.yahoo.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesJanuary 20, 2024 | benzinga.comAnebulo Pharmaceuticals Stock (NASDAQ:ANEB) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comAnebulo Pharmaceuticals, Inc. (ANEB)December 17, 2023 | nasdaq.comAnebulo Pharmaceuticals (FRA:214) Price Target Increased by 21.00% to 6.80December 9, 2023 | morningstar.comAnebulo Pharmaceuticals Inc ANEBSee More Headlines Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)9/18/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANEB CUSIPN/A CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$6.67 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+203.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-122.98% Return on Assets-109.29% Debt Debt-to-Equity RatioN/A Current Ratio5.32 Quick Ratio5.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book5.37Miscellaneous Outstanding Shares25,930,000Free Float3,657,000Market Cap$57.05 million OptionableNot Optionable Beta-0.98 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Joseph F. Lawler M.D. (Age 52)Ph.D., Founder & Chairman Comp: $11kDr. Kenneth C. Cundy Ph.D. (Age 65)Chief Scientific Officer Comp: $425.15kMr. Richard Anthony Cunningham (Age 53)CEO & Director Mr. Daniel V. George (Age 54)Principal Accounting Officer, Acting CFO & Secretary Mr. Scott L. AndersonHead of Investor Relations & Public AffairsKey CompetitorsSatsuma PharmaceuticalsNASDAQ:STSASol-Gel TechnologiesNASDAQ:SLGLOpiant PharmaceuticalsNASDAQ:OPNTOptiNoseNASDAQ:OPTNESSA PharmaNASDAQ:EPIXView All Competitors ANEB Stock Analysis - Frequently Asked Questions How have ANEB shares performed this year? Anebulo Pharmaceuticals' stock was trading at $2.42 on January 1st, 2024. Since then, ANEB shares have decreased by 9.1% and is now trading at $2.20. View the best growth stocks for 2024 here. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) announced its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. When did Anebulo Pharmaceuticals IPO? Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO. How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANEB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.